William Aird: Standardizing Anemia, Thrombocytopenia, and Neutropenia Cutoffs
William Aird, Professor of Medicine at Harvard Medical School, posted on X:
“MILD, MODERATE, SEVERE… ACCORDING TO WHO?
I often notice MDs describing cytopenias as “mild,” “moderate,” or “severe” without reference to standard definitions.
The problem? Severity is in the eye of the beholder. Without shared definitions, these terms lose precision.

Of course, no one will argue if you call a platelet count of 143k “mild.”
But in teaching, communication, and especially clinical trials, it’s important to anchor our language to standardized thresholds so we’re all speaking the same language.
The graphic in this tweet summarizes commonly used cutoffs for anemia, thrombocytopenia, and neutropenia, based on guidelines and consensus in the literature.
Clear definitions help keep us on the same page, in both patient care and research!
As much as I endorse standardized definitions, I’d find it more helpful if “severe anemia” aligned better with our transfusion threshold (~7 g/dL). Also, there’s a big difference between a hemoglobin of 7.9 (severe by WHO) and 4.0 in the ED. How ’bout a bit more granularity?”
Stay updated with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia
